Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) CFO Mark K. Oki purchased 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $28,900. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Achieve Life Sciences Stock Performance
ACHV stock opened at $2.67 on Thursday. The business's fifty day moving average is $3.12 and its 200-day moving average is $3.97. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. The company has a market cap of $92.61 million, a P/E ratio of -2.36 and a beta of 1.67. Achieve Life Sciences, Inc. has a twelve month low of $2.51 and a twelve month high of $5.59.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06). Equities research analysts forecast that Achieve Life Sciences, Inc. will post -1.17 EPS for the current year.
Institutional Trading of Achieve Life Sciences
Several hedge funds have recently added to or reduced their stakes in ACHV. MetLife Investment Management LLC raised its stake in Achieve Life Sciences by 65.6% during the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 5,939 shares during the period. Verition Fund Management LLC bought a new position in Achieve Life Sciences during the 3rd quarter worth about $113,000. State Street Corp increased its holdings in Achieve Life Sciences by 6.8% during the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company's stock worth $2,045,000 after purchasing an additional 27,419 shares in the last quarter. Barclays PLC increased its holdings in Achieve Life Sciences by 303.1% during the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company's stock worth $226,000 after purchasing an additional 35,832 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company's stock worth $3,552,000 after purchasing an additional 48,474 shares in the last quarter. Institutional investors and hedge funds own 33.52% of the company's stock.
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
